GlassScriptPhysician profile
Gueorgui D Gueorguiev
NPI 1790719243
$1,194.97
in general payments reported to CMS, 2019-2025
28 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.26 · 2020: $97.95 · 2021: $230 · 2022: $233 · 2023: $98.87 · 2024: $251 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $142.78 | 2021-2024 | |
| Amgen INC. | $127.16 | 2021-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $126.29 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $124.25 | 2019-2025 | |
| Allergan, INC. | $61.73 | 2020 | |
| Novo Nordisk INC | $59.07 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $57.69 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $53.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $48.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.98 | 2019 | |
| Amarin Pharma, INC. | $37.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $28.30 | 2025 | Zoryve |
| Baudax Bio INC. | $28.08 | 2021 | |
| Harmony Biosciences LLC | $25.33 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $23.37 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.40 | 2023 | Xywav |
| Organon LLC | $21.54 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $19.57 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $17.79 | 2022 | |
| Esperion Therapeutics, INC. | $16.03 | 2021 | |
| Exact Sciences Corporation | $15.43 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $15.41 | 2022 | |
| Acadia Pharmaceuticals INC | $15.31 | 2023 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $13.83 | 2021 | |
| Organogenesis INC. | $13.81 | 2025 | Via Matrix |
| Sanofi-Aventis U.S. LLC | $12.34 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gueorgui Gueorguiev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.